Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
Radiat Oncol. 2021 Oct 30;16(1):208. doi: 10.1186/s13014-021-01934-y.
Through recent advances in cancer care, the number of long-term survivors has continuously increased. As a result, repetitive use of local radiotherapy for curative or palliative indications might have increased as well. This analysis aims to describe patterns of care and outcome of patients treated with multiple courses of repeat radiotherapy.
All patients treated with radiotherapy between 2011 and 2019 at our department of Radiation Oncology were included into this analysis. A course of radiotherapy was defined as all treatment sessions to one anatomical site under one medical indication. Demographics, cancer and treatment characteristics and overall survival of patients having undergone multiple radiotherapy courses (minimum n = 5) were evaluated.
The proportion of cancer patients treated with a minimum five courses of radiotherapy increased continuously from 0.9% in 2011 to 6.5% in 2019. In the 112 patients treated with a minimum of five radiotherapy courses, the primary tumor was lung in 41.9% (n = 47), malignant melanoma in 8.9% (n = 10) and breast in 8.0% (n = 9) of cases. A median interval of 3 years (maximum 8 years) elapsed between the first and the last radiotherapy course. The maximum number of courses in a single patient were n = 10. Treatment intent was curative or palliative in 46.4% and 53.6% for the first radiotherapy, respectively. The proportion of curative intent decreased to 11.6% at the 5th, and the last radiotherapy course was following a palliative intent in all patients. Five-year overall survival measured from the 1st radiotherapy course was 32.7%. Median overall survival was 3.3, 2.4, 1.3, and 0.6 years when measured from the 1st, the 1st palliative, the 5th and last course of radiotherapy, respectively.
A continuously increasing number of patients is treated with multiple courses of radiotherapy throughout their long-term cancer survivorship.
随着癌症治疗的最新进展，长期幸存者的数量不断增加。因此，出于治愈或姑息治疗的目的，重复使用局部放疗的情况可能也有所增加。本分析旨在描述接受多次重复放疗的患者的治疗模式和结局。
本分析纳入了 2011 年至 2019 年期间在我院放射肿瘤科接受放疗的所有患者。一个疗程的放疗被定义为在一个医疗适应症下对一个解剖部位的所有治疗阶段。评估了接受多次放疗（至少 n=5）的患者的人口统计学、癌症和治疗特征以及总生存情况。
接受至少 5 个疗程放疗的癌症患者比例从 2011 年的 0.9%持续增加到 2019 年的 6.5%。在接受至少 5 个放疗疗程的 112 名患者中，原发肿瘤为肺癌的占 41.9%（n=47），恶性黑色素瘤占 8.9%（n=10），乳腺癌占 8.0%（n=9）。首次放疗和末次放疗之间的中位间隔为 3 年（最长 8 年）。单个患者接受的最大疗程数为 n=10。首次放疗的治疗目的为治愈或姑息性的分别占 46.4%和 53.6%。第 5 次和末次放疗的治疗目的均为姑息性，治愈目的的比例分别降至 11.6%和 100%。从首次放疗开始计算的 5 年总生存率为 32.7%。从首次、首次姑息性、第 5 次和末次放疗开始计算的中位总生存期分别为 3.3、2.4、1.3 和 0.6 年。
随着长期癌症生存者人数的不断增加，越来越多的患者接受了多次放疗。
